NewMoneyMoves
PerspectivesResearchTerminalsWeekend RWABoard
HomeEarningsEli Lilly and Company FY2025 Q2
Released
FY2025 Q2
Earnings Review
LLY
BEAT

Eli Lilly and Company

Eli Lilly and Company · Pharmaceuticals/Biotech

Mon, June 30, 2025·After Market Close
Pharmaceuticals/BiotechLLYEarnings

01Wall Street Consensus

EPS$5.59
Revenue$15.6B

02Earnings Results

EPS$6.31+12.9%
Revenue$15.6BN/A

Key Checkpoints

    Upside Catalysts

      Risk Factors

        Detail

        EEPS History (Last 12 Quarters)

        Actual EPS vs Consensus — Green Beat · Red Miss

        Beat9
        Miss3
        Beat rate75%
        Detail

        SEPS 서프라이즈 히스토리

        Beat9Miss3Beat률 75%

        분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출

        컨센서스 대비 실제 EPS/매출 서프라이즈 (%)

        Comments

        Earnings
        Earnings Info
        SymbolLLY
        QuarterFY2025 Q2
        Report Date2025-06-30
        Report TimeAMC
        SectorPharmaceuticals/Biotech
        StatusReleased
        Wall Street Consensus
        EPS$5.59
        Revenue$15.6B
        Results
        Actual EPS$6.31
        Actual Revenue$15.6B
        NewMoneyMoves

        Global Investment through Themes

        Content

        ThemesIdeasReportsEarnings

        Explore

        GuideETFsPerspectivesTelegramNVIDIA PortfolioWeekly ReviewCredit & Leverage

        Community

        Daily News

        Legal

        Privacy PolicyTerms of ServiceDisclaimer

        © 2026 NewMoneyMoves. All rights reserved.